Diagenode

Induction of epithelial-mesenchymal transition (EMT) by hypoxia-inducedlncRNA through regulating the histone 4 lysine 16 acetylation(H4K16Ac) mark.


Peng P-H et al.

Hypoxia activates various long noncoding RNAs (lncRNAs) to induce the epithelial-mesenchymal transition (EMT) and tumor metastasis. The hypoxia/HIF-1α-regulated lncRNAs that also regulate a specific histone mark and promote EMT and metastasis have not been identified. We performed RNA-sequencing dataset analysis to search for such lncRNAs and lncRNA was the hypoxia-induced lncRNA with the highest hazard ratio. High expression of lncRNA is correlated with a worse survival of head and neck cancer patients. We further showed that lncRNA is induced by hypoxia and directly regulated by HIF-1α in cell lines. Overexpression of lncRNA induces the EMT and increases the migration and invasion and metastatic activity. Knockdown experiments showed that lncRNA plays an essential role in hypoxia-induced EMT. LncRNA specifically regulates the histone 4 lysine 16 acetylation (H4K16Ac) mark that is located on the promoters of two "core" EMT regulators, and , and genes. These results indicate that lncRNA regulates the deposition of H4K16Ac on the promoters of target genes to activate their expression. This report identifies lncRNA as a key player in regulating the histone mark H4K16Ac through which activates downstream target genes to mediate hypoxia-induced EMT.

Tags
Antibody

Share this article

Published
January, 2021

Source

Events

  • London Calling 2024
    London, UK
    May 21-May 24, 2024
  • Symposium of the Young Scientist Association
    Vienna, Austria
    May 28-May 29, 2024
  • ESHG 2024
    Berlin, Germany
    Jun 1-Jun 4, 2024
  • CLEPIC 2024
    Warsaw, Poland
    Jun 5-Jun 7, 2024
  • EACR 2024
    Rotterdam, Netherlands
    Jun 10-Jun 13, 2024
  • Chromatin meets South 2024
    Marseille, France
    Jun 13-Jun 14, 2024
 See all events

 


       Site map   |   Contact us   |   Conditions of sales   |   Conditions of purchase   |   Privacy policy   |   Diagenode Diagnostics